Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Botulinum Toxin Type A

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: Botulinum Toxin Type A. Displaying page 12 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12 
    EudraCT Number: 2020-005553-24 Sponsor Protocol Number: SN-SPAS-201 Start Date*: 2021-07-07
    Sponsor Name:Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
    Full Title: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-La...
    Medical condition: Upper Limb Spasticity
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004384-31 Sponsor Protocol Number: MT10109L-001 Start Date*: 2019-08-07
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines.
    Medical condition: Glabellar Lines
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005279-10 Sponsor Protocol Number: MT10109L-002 Start Date*: 2019-09-24
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
    Medical condition: Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-005302-38 Sponsor Protocol Number: MT10109L-006 Start Date*: 2019-12-18
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines Wi...
    Medical condition: Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002346-37 Sponsor Protocol Number: 191622-127 Start Date*: 2014-05-21
    Sponsor Name:Allergan Limited
    Full Title: BOTOX® Treatment in Adult Patients with Upper Limb Spasticity
    Medical condition: Poststroke spasticity involving the muscles of the elbow and shoulder in adult patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10041416 Spasticity LLT
    17.0 100000004852 10042244 Stroke LLT
    17.0 100000004852 10048970 Arm spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000464-17 Sponsor Protocol Number: 191622-137 Start Date*: 2014-06-17
    Sponsor Name:Allergan Limited
    Full Title: BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age
    Medical condition: Urinary Incontinence Due to Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) NO (Completed) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004877-26 Sponsor Protocol Number: 191622-120 Start Date*: 2013-07-18
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
    Medical condition: Urinary Incontinence Due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007478-39 Sponsor Protocol Number: 42160443NPP2001 Start Date*: 2009-10-07
    Sponsor Name:Janssen Cilag International, NV
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-T...
    Medical condition: Postherpetic Neuralgia and Post-Traumatic Neuralgia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029223 Neuralgia LLT
    9.1 10036376 Post herpetic neuralgia LLT
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 17:59:08 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA